Profound Medical Corp.

NasdaqCM:PROF Stock Report

Market Cap: US$217.2m

Profound Medical Management

Management criteria checks 3/4

Profound Medical's CEO is Arun Menawat, appointed in Aug 2016, has a tenure of 8.33 years. total yearly compensation is $889.95K, comprised of 41.6% salary and 58.4% bonuses, including company stock and options. directly owns 2.28% of the company’s shares, worth $4.96M. The average tenure of the management team and the board of directors is 1.9 years and 3.8 years respectively.

Key information

Arun Menawat

Chief executive officer

US$889.9k

Total compensation

CEO salary percentage41.6%
CEO tenure8.3yrs
CEO ownership2.3%
Management average tenure1.9yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Profound Medical Q2 GAAP EPS beats, revenue in-line

Aug 04

Profound Medical Lacks Conviction To Overthrow Macro Headwinds

Jul 10

CEO Compensation Analysis

How has Arun Menawat's remuneration changed compared to Profound Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$31m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023US$890kUS$370k

-US$29m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$916kUS$344k

-US$29m

Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$30m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$4mUS$481k

-US$31m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$2mUS$1m

-US$22m

Sep 30 2020n/an/a

-US$18m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$2mUS$531k

-US$15m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019n/an/a

-US$14m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$672kUS$509k

-US$15m

Sep 30 2018n/an/a

-US$16m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$15m

Dec 31 2017US$264kUS$264k

-US$15m

Compensation vs Market: Arun's total compensation ($USD889.95K) is below average for companies of similar size in the US market ($USD1.44M).

Compensation vs Earnings: Arun's compensation has been consistent with company performance over the past year.

CEO

Arun Menawat (69 yo)

8.3yrs

Tenure

US$889,948

Compensation

Dr. Arun Swarup Menawat, Ph D., MBA, serves as an Independent Director of Firefly Neuroscience, Inc. and served as its Chairman. He serves as the Chairman at Profound Medical Corp. Dr. Menawat has been the...

Leadership Team

NamePositionTenureCompensationOwnership
Arun Menawat
Chairman of the Board & CEO8.3yrsUS$889.95k2.28%
$ 5.0m
Mathieu Burtnyk
Presidentless than a yearUS$396.81k0.13%
$ 284.1k
Rashed Dewan
Chief Financial Officer3.6yrsUS$669.26k0.19%
$ 412.6k
Stephen Kilmer
Investor Relationsno datano datano data
Thomas Tamberrino
Chief Commercial Officerless than a yearno data0.054%
$ 117.4k
Matthew Sobczyk
Assistant Corporate Controllerno datano datano data
Levant Tinaz
Software Developerno datano datano data

1.9yrs

Average Tenure

56yo

Average Age

Experienced Management: PROF's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Arun Menawat
Chairman of the Board & CEO9.5yrsUS$889.95k2.28%
$ 5.0m
Arthur L. Rosenthal
Independent Director6.5yrsUS$101.96k0.070%
$ 152.4k
Brian Ellacott
Independent Lead Director6.5yrsUS$102.91k0.28%
$ 598.9k
Cynthia Lavoie
Independent Director3.8yrsUS$97.91k0.027%
$ 59.3k
Mark Emberton
Member of Clinical Advisory Boardno datano datano data
Kris Shah
Independent Director2.6yrsUS$96.96kno data
Murielle Lortie
Independent Director4.1yrsUS$100.41k0.013%
$ 27.7k
Laurence Klotz
Member of Clinical Advisory Board2.2yrsno datano data
Adam Kibel
Member of Clinical Advisory Boardno datano datano data
Aytekin Oto
Member of Clinical Advisory Boardno datano datano data
Edward Steiner
Member of Clinical Advisory Board2.2yrsno datano data
Naveen Kella
Member of Clinical Advisory Board2.2yrsno datano data

3.8yrs

Average Tenure

65yo

Average Age

Experienced Board: PROF's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 02:55
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Profound Medical Corp. is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David KideckelBeacon Securities Limited
Jason MillsCanaccord Genuity
Prakash GowdCIBC Capital Markets